The guideline recommendations advise universal use of hydroxychloroquine, minimizing steroids, and earlier introduction of ...

T-cell therapy for rheumatologic disease is now expanding out of academe into the commercial space, with encouraging new data ...

AstraZeneca Plc said a handful of patients with lupus went into remission after getting an experimental treatment, as the UK ...

BARCELONA -- A novel antibody-based drug targeting the CD40 ligand helped close to half of patients with treatment-refractory ...

This mysterious autoimmune disease presents with over 100 different symptoms, making diagnosis incredibly challenging for ...

Full results from the first phase 3 trial of UCB and Biogen's anti-CD40L antibody dapirolizumab pegol (DZP) in systemic lupus ...

Most lupus patients are women and many are Black women. They can suffer rashes, fatigue and kidney problems but may not know ...

Merck KGaA has shed more light on the failure of its lupus drug in one cohort of patients, while pointing to secondary ...

The Member of Parliament (MP) for Korle Klottey in Accra, Dr Zanetor Agyeman-Rawlings, has called for the inclusion of lupus ...

Margrit Wiesendanger, MD, PhD, highlights how social determinants of health and equitable treatment access are critical to improving lupus outcomes, particularly in minority populations.

The global cutaneous lupus erythematosus market is experiencing significant growth, driven by novel biologic therapies and personalized medicine. With rising autoimmune disease incidence, enhanced ...